Why Spain thinks Novo Nordisk may be illegally advertising Ozempic
Spain is investigating the drugmaker Novo Nordisk over concerns that it may be illegally advertising its blockbuster weight loss drugs Ozempic and Wegovy.
It is the latest in a string of inquiries into the Danish pharmaceutical giant, with authorities in at least two other European countries accusing Novo Nordisk of unlawfully promoting its medications in recent years.
The drugs, which were created to treat obesity and type 2 diabetes, work by mimicking a hormone in the body that makes people feel full for longer. They have surged in popularity because they help people lose weight quickly.
But health officials worry that drugmakers are seeking to boost already sky-high demand, possibly in violation of a European Union ban on consumer advertising for drugs that can only be obtained via prescription.
Pharmaceutical companies are both 'creating awareness of the disease [and] selling the drug' to treat it, Javier Padilla , Spain's secretary of state for health, told Euronews Health.
The latest kerfuffle involves a campaign that Novo Nordisk launched in Spain earlier this month to raise public awareness about the health risks of obesity with the tagline 'Obesidad Sin Filtros,' or 'Obesity Without Filters'.
The company also launched a website – which has since been taken down – on obesity's health risks that cited endorsements from key scientific societies, recommended questions for people to ask their doctors, and offered weight loss tips.
Notably, these tips included a healthy diet, exercise, and sleep, and did not explicitly mention any medicines.
Even so, the Spanish health ministry said the campaign could serve as 'covert advertising' for Novo Nordisk's weight loss drugs.
'It's widely known that if Novo Nordisk is talking about obesity, it is because it is talking about Ozempic,' Padilla said, calling the campaign 'very obvious'.
Padilla said the health ministry asked Novo Nordisk to provide more details on how the campaign came together, including what the professional societies knew about the materials beforehand. If it finds the company has violated EU law, he said the Spanish government may slap it with a fine.
A Novo Nordisk spokesperson defended the initiative, telling Euronews Health the company worked with medical societies to develop the campaign and that it is in 'good active dialogue with the authorities' in Spain.
'Obesity is not a character flaw, but a chronic disease… [and] we continue to confront the stigma and bias associated with it and advocate for access to support and care,' the spokesperson added.
Which other countries have taken aim at Novo Nordisk?
Other countries have also scrutinised Novo Nordisk's tactics in recent years. Last month, the Irish Times reported that Ireland's medicines watchdog found the company had broken rules around marketing to healthcare workers over a three-year period.
Meanwhile, the United Kingdom's pharmaceutical lobby reinstated Novo Nordisk's membership in March after a two-year suspension for engaging in misleading marketing practices.
Novo Nordisk is not the only drugmaker under scrutiny. According to Padilla, the Spanish health ministry is also probing Eli Lilly, which makes rival weight loss jab Mounjaro.
Padilla called on other European countries to crack down on pharmaceutical companies that appear to toe the line between health promotion and drug advertising – particularly those selling weight loss drugs, which are expected to strain national budgets in the coming years.
'If more governments were more proactive in these situations, it would result in companies being less brave' about pushing the limits on marketing rules, Padilla said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
France 24
5 hours ago
- France 24
Greenland, breaking the silence: The scandal of Denmark's forced contraception campaign
Europe 36:03 In 1960s Greenland, thousands of young Inuit girls – some barely teenagers – were sent to hospital. Without giving an explanation or obtaining their consent, Danish doctors fitted them with IUDs, a painful procedure that left lifelong scars. In total, more than 4,500 Greenlandic women were victims of this mass forced contraception campaign, orchestrated by the Danish authorities. FRANCE 24's Sarah Andersen has been to meet victims who are now demanding justice.
Euronews
6 hours ago
- Euronews
Why Spain thinks Novo Nordisk may be illegally advertising Ozempic
Spain is investigating the drugmaker Novo Nordisk over concerns that it may be illegally advertising its blockbuster weight loss drugs Ozempic and Wegovy. It is the latest in a string of inquiries into the Danish pharmaceutical giant, with authorities in at least two other European countries accusing Novo Nordisk of unlawfully promoting its medications in recent years. The drugs, which were created to treat obesity and type 2 diabetes, work by mimicking a hormone in the body that makes people feel full for longer. They have surged in popularity because they help people lose weight quickly. But health officials worry that drugmakers are seeking to boost already sky-high demand, possibly in violation of a European Union ban on consumer advertising for drugs that can only be obtained via prescription. Pharmaceutical companies are both 'creating awareness of the disease [and] selling the drug' to treat it, Javier Padilla , Spain's secretary of state for health, told Euronews Health. The latest kerfuffle involves a campaign that Novo Nordisk launched in Spain earlier this month to raise public awareness about the health risks of obesity with the tagline 'Obesidad Sin Filtros,' or 'Obesity Without Filters'. The company also launched a website – which has since been taken down – on obesity's health risks that cited endorsements from key scientific societies, recommended questions for people to ask their doctors, and offered weight loss tips. Notably, these tips included a healthy diet, exercise, and sleep, and did not explicitly mention any medicines. Even so, the Spanish health ministry said the campaign could serve as 'covert advertising' for Novo Nordisk's weight loss drugs. 'It's widely known that if Novo Nordisk is talking about obesity, it is because it is talking about Ozempic,' Padilla said, calling the campaign 'very obvious'. Padilla said the health ministry asked Novo Nordisk to provide more details on how the campaign came together, including what the professional societies knew about the materials beforehand. If it finds the company has violated EU law, he said the Spanish government may slap it with a fine. A Novo Nordisk spokesperson defended the initiative, telling Euronews Health the company worked with medical societies to develop the campaign and that it is in 'good active dialogue with the authorities' in Spain. 'Obesity is not a character flaw, but a chronic disease… [and] we continue to confront the stigma and bias associated with it and advocate for access to support and care,' the spokesperson added. Which other countries have taken aim at Novo Nordisk? Other countries have also scrutinised Novo Nordisk's tactics in recent years. Last month, the Irish Times reported that Ireland's medicines watchdog found the company had broken rules around marketing to healthcare workers over a three-year period. Meanwhile, the United Kingdom's pharmaceutical lobby reinstated Novo Nordisk's membership in March after a two-year suspension for engaging in misleading marketing practices. Novo Nordisk is not the only drugmaker under scrutiny. According to Padilla, the Spanish health ministry is also probing Eli Lilly, which makes rival weight loss jab Mounjaro. Padilla called on other European countries to crack down on pharmaceutical companies that appear to toe the line between health promotion and drug advertising – particularly those selling weight loss drugs, which are expected to strain national budgets in the coming years. 'If more governments were more proactive in these situations, it would result in companies being less brave' about pushing the limits on marketing rules, Padilla said.
Euronews
a day ago
- Euronews
Europe leads global vaccine effort as US pulls back
At a high-level pledging event in Brussels on Thursday, the GAVI Vaccine Alliance rallied international donors to fund its next five-year programme. So far, GAVI has secured over €7.7 billion – still short of its overall target, though more pledges are expected in the coming weeks. "What's at stake is the lives of millions and millions of children. And I think there is nothing more important in the world than the lives of millions of children," GAVI Chairman José Manuel Barroso told Euronews in an interview. 'It makes a difference if they get immunisation, if they get vaccines or not. Because if they don't get them, they will die from perfectly preventable diseases," he added. GAVI, launched in 2000, is a global health partnership aimed at improving vaccine access in the world's poorest countries. Since its inception, the alliance has helped vaccinate over one billion children and is estimated to have saved 19 million lives. Now, it aims to reach 500 million more by 2030. Supporters say vaccine investments offer a strong return – up to $54 for every dollar spent – through reduced healthcare costs and increased economic productivity. Europe Leads the Charge European nations were among the most prominent backers at the Brussels event. Spain's Prime Minister Pedro Sánchez pledged €130 million, 30% more than the country's previous commitment. 'Spain is ready to take a step forward when others are backing down,' he said. The European Commission also reaffirmed its support with a €360 million pledge, bringing the total 'Team Europe' commitment — combining EU institutions and member states — to more than €2 billion. Commission President Ursula von der Leyen welcomed GAVI and UNICEF's commitment to procure up to 20% of vaccines in their programmes from African producers. 'Together we can ensure that vaccines are not only available to Africa, but increasingly made in Africa,' she said at the event, mentioning that Europe is also the largest contributor to the Africa vaccine manufacturing accelerator. The United Kingdom emerged as the single largest donor, committing £1.25 billion. 'Where others are stepping back, we in the United Kingdom are stepping up,' said UK Foreign Secretary David Lammy. 'This will help immunise over 60 million children, saving an estimated 1.25 million lives.' United States pulls out In a stark contrast to past years, the United States — historically a major donor to GAVI — announced it would no longer provide funding, as part of a broader reduction in international aid under President Donald Trump's administration. 'There is much I admire about GAVI,' said US Health Secretary Robert F. Kennedy Jr. in a video message. 'Unfortunately, in its zeal to promote universal vaccination, it has neglected the key issue of vaccine safety.' Kennedy, a known vaccine sceptic, specifically raised concerns about the DTP vaccine (diphtheria, tetanus, and pertussis), a widely used childhood immunisation. GAVI responded by reaffirming its "full confidence" in the DTP vaccine, citing decades of rigorous safety monitoring. Barroso, in a separate interview prior to Kennedy's statement, maintained an optimistic tone about future collaboration with the US administration. However, he also denounced vaccine disinformation campaigns fuelled by conspiracy theories and social media. 'People, sometimes, like to accept these kinds of fantasies,' he said. As Barroso concluded, the global data on vaccination impact is indisputable: countries with sustained immunisation programmes have seen drastically lower child mortality rates. Preventable diseases like polio, once widespread, have nearly disappeared in these regions. "Vaccines save lives and that's hard evidence," he said.
